Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives

Lurbinectedin is an antitumor agent belonging to the natural marine-based tetrahydroisoquinoline family which has shown very promising clinical activity with a favorable safety profile in many types of cancer. Preclinical evidence showed that lurbinectedin inhibits active transcription and binds to...

Descripción completa

Detalles Bibliográficos
Autores principales: Musacchio, Lucia, Cicala, Carlo Maria, Salutari, Vanda, Camarda, Floriana, Carbone, Maria Vittoria, Ghizzoni, Viola, Giudice, Elena, Nero, Camilla, Perri, Maria Teresa, Ricci, Caterina, Tronconi, Francesca, Scambia, Giovanni, Lorusso, Domenica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904915/
https://www.ncbi.nlm.nih.gov/pubmed/35280728
http://dx.doi.org/10.3389/fonc.2022.831612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904915/
https://www.ncbi.nlm.nih.gov/pubmed/35280728
http://dx.doi.org/10.3389/fonc.2022.831612

Ejemplares similares